BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels

B-Rapidly Accelerated Fibrosarcoma (BRAF) mutations are found in about 50% of melanoma patients. Treatment with Food and Drug Administration (FDA)-approved BRAF and MAP/ERK kinase (MEK) inhibitors has improved progression free and overall survival of patients with BRAF mutant melanoma. However, all...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Long, Mishra, Rosalin, Patel, Hima, Alanazi, Samar, Wei, Xin, Ma, Zhijun, Garrett, Joan T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352565/
https://www.ncbi.nlm.nih.gov/pubmed/32585852
http://dx.doi.org/10.3390/cancers12061661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352565/
https://www.ncbi.nlm.nih.gov/pubmed/32585852
http://dx.doi.org/10.3390/cancers12061661

Ejemplares similares